Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
adversarial, AG, aggressive, alter, anniversary, annuity, antagonist, antibody, array, assert, assignee, assumed, backup, billion, Biopharma, biosimilar, block, blocking, breadth, broad, brownian, cancellation, Carlo, certainty, cessation, checkpoint, circumvented, CMO, commonplace, conceived, conclusion, concurrent, concurrently, conferred, configured, consecutive, contrast, correct, counsel, crowded, cumulative, Curetech, curtail, cycle, declaratory, degree, desirable, desired, Display, dispute, distraction, documentary, dominant, downstream, dual, earliest, effort, envision, exacerbate, exceeding, familiarity, family, fee, flexibility, forma, found, Franc, freedom, functional, geometric, Germany, GITR, halt, hampered, hand, headcount, herpetic, identification, ii, iii, illustrative, impinge, implied, impractical, inadvertent, inadvertently, IND, indirectly, intangible, inter, introduce, inventor, inventorship, ipilimumab, IV, January, jeopardize, lag, landscape, lapse, lead, leading, leave, lesion, lifetime, literature, Ludwig, maintenance, managerial, Medimmune, misappropriate, missed, mix, modulator, molecular, monoclonal, monospecific, Monte, motion, narrowed, narrower, noncompliance, opposition, optimization, optimize, organized, pro, procedural, proceed, ramp, rapid, reactive, readout, Recepta, reexamination, reinstated, relief, remind, retired, Retrocyte, rightfully, SA, SEC, secret, sequence, shelf, shift, simulation, site, sought, Squibb, stable, suitable, supplemental, Switzerland, synergy, tangible, Tesaro, threat, throughput, treasury, trending, underwritten, unenforceable, unissued, unlikelihood, viability, vulnerability, yearly, Yervoy
Removed:
America, AOCI, BLA, brain, build, California, Canada, center, CEO, clarify, cognizant, consulting, consume, contemplated, contracted, creditable, dated, decision, detail, diminished, duration, enforced, enjoined, entirety, equivalent, ESPP, Europe, European, expectation, exploit, exploring, Francisco, free, generating, governed, HSP, identical, importing, instituted, invent, long, nonrefundable, offset, partially, passage, post, progression, proliferation, proposed, provoked, reclassification, reclassified, reference, reflected, reform, refuse, Restated, reviewing, San, screening, select, send, Separately, September, sizable, source, stopping, subcontract, subsequently, suggesting, survival, tested, thereon, thereunder, unclear, underway, untested, untried, upheld, violated, virtually, yielded
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Collaborative Research and Development Agreement
- 10.2 Collaborative Research and Development Agreement
- 10.3 Sublease Agreement
- 10.3.1 Amendment to Sublease
- 10.3.2 Amendment 4 to Sublease
- 10.3.3 Amendment 5 to Sublease
- 10.3.4 Amendment 6 to Sublease
- 10.4 Commercial Lease Agreement
- 10.4.1 Amendment 20 to Commercial Lease
- 10.4.2 Amendment 28 to Commercial Lease
- 10.4.3 Amendment 29 to Commercial Lease
- 31.1 Certificate of CEO Pursuant to Section 302
- 31.2 Certificate of Pfo Pursuant to Section 302
- 32.1 Certificate of CEO and Pfo Pursuant to Section 906
- Download Excel data file
- View Excel data file
Related press release
AGEN similar filings
Filing view
External links
29th Addendum to the BioCentiv – 4-Antibody Lease Agreement from 08/09/2013
BioCentiv [logo]
29th Addendum
to Lease Agreement No. 01/2003
from 12/01/2002
BioCentiv GmbH (Lessor)
and 4-Antibody AG (Lessee)
amend the above-mentioned Lease Agreement per 09/01/2013 as follows:
Section 4 Rent, other payments
(1) b The prepaid incidental expenses from September to December 2013 are set to €7,959.93.
The prepaid incidental expenses starting January 2014 are set to €6,279.98.
Starting 09/01/2013–12/31/2013, the total monthly rent is as follows:
Subtotal rent, net | €8,891.11 | ||
Center’s flat charge, net | €859.20 | ||
Prepaid incidental expenses | €7,959.93 | ||
Total rent, net | €17,710.24 | ||
19% VAT | €3,364.95 | ||
Total rent, gross | €21,075.19 |
Starting 01/01/2014, the total monthly rent is as follows:
Subtotal rent, net | €8,891.11 | ||
Center’s flat charge, net | €859.20 | ||
Prepaid incidental expenses | €6,279.98 | ||
Total rent, net | €16,030.29 | ||
19% VAT | €3,045.76 | ||
Total rent, gross | €19,076.05 |
Page 1 of 2
29th Addendum to the BioCentiv – 4-Antibody Lease Agreement from 08/09/2013
BioCentiv [logo]
All other provisions of the Lease Agreement remain in effect.
Jena, 08/09/2013
BioCentiv GmbH | 4-Antibody AG Germany Branch | |
[signature] Dr. Klaus Ullrich Director | [signature] Dr. Robert Burns Director | [signature] Dr. Luis Martin-Parras Authorized Agent |
Page 2 of 2